Table 3. Comparison of protective rates according to vaccination schedule in different at-risk populations.
| Accelerated | Ref. | Sample | RR (95%CI) (IV, Random) | |
|---|---|---|---|---|
| schedule | size (ITT/PP) | ITT | PP | |
| 1st month after initial dose | ||||
| 0–7–21 days | 3 | 600/596 | 2.86(2.27,3.62) | 2.88(2.28,3.64) |
| 0–14–42 days | 1 | 53/53 | 12.52(1.76,88.99) | 12.52(1.76,88.99) |
| 0–7–28–56 days | 1 | 169/169 | 4.69(1.67,13.22) | 4.69(1.67,13.22) |
| 0–1–2–12 months | 2 | 480/467 | 1.31(0.81,2.12) | 1.36(0.84,2.19) |
| 3rd month after initial dose | ||||
| 0–7–21 days | 1 | 100/100 | 1.03(0.82,1.29) | 1.03(0.82,1.29) |
| 0–14–42 days | 1 | 53/53 | 2.01(1.25,3.24) | 2.01(1.25,3.24) |
| 0–1–2 months | 1 | 230/217 | 1.28(1.11,1.46) | 1.31(1.17,1.48) |
| 0–1–2–12 months | 2 | 399/358 | 1.16(1.02,1.32) | 1.19(1.06,1.34) |
| 7th month after initial dose | ||||
| 0–7–21 days | 2 | 300/295 | 0.98(0.91,1.06) | 0.98(0.92,1.06) |
| 0–14–42 days | 1 | 53/52 | 1.04(0.94,1.15) | 1.00(0.93,1.08) |
| 0–7–28–56 days | 1 | 169/161 | 0.93(0.81,1.08) | 0.84(0.74,0.96) |
| 0–1–2 months | 1 | 230/205 | 0.93(0.84,1.02) | 0.98(0.94,1.02) |
| 0–1–2–12 months | 3 | 514/461 | 0.92(0.82,1.03) | 0.92(0.87,0.98) |
| 12th month after initial dose | ||||
| 0–7–21 days | 2 | 400/390 | 0.97(0.89,1.07) | 0.96(0.88,1.05) |
| 0–1–2–12 months | 3 | 593/525 | 0.95(0.89,1.01) a | 1.02(0.97,1.07) a |
| >22 months after initial dose | ||||
| 0–7–21 days | 2 | 500/471 | 0.92(0.82,1.05) | 0.93(0.82,1.04) |
a13 month for the trial group. RR = relative risk; CI = confidence interval; IV = inverse variance; ITT = intention-to-treat; PP = per-protocol. Bold fonts indicate statistical significance (P<0.05).